BAO PHARMA-B repurchases 101,700 H-shares for HK$1.99 million; treasury stock rises to 834,900 shares

Bulletin Express07-13 18:42

Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B) disclosed on 13 July 2026 that it bought back 101,700 H-shares on the Hong Kong Stock Exchange. The transaction, executed under the company’s existing repurchase mandate, was completed at prices between HK$19.20 and HK$20.24 per share, with a volume-weighted average cost of HK$19.61 per share, bringing the total cash outlay to HK$1.99 million.

Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 153.49 million, down from 153.59 million prior to the transaction. Treasury shares increased to 834,900, while the company’s total issued share count, including treasury shares, remained unchanged at 154.33 million.

The shares were repurchased under the authority granted by shareholders on 26 May 2026, which allows the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 834,900 shares, representing 0.54% of the issued share capital as of the mandate date.

In line with Hong Kong listing rules, BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 August 2026. The board confirmed that the repurchase was duly authorised and executed in full compliance with all applicable regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182059482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182059482","market":"hk","top_or_hot":-1,"title":"BAO PHARMA-B repurchases 101,700 H-shares for HK$1.99 million; treasury stock rises to 834,900 shares","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B) disclosed on 13 July 2026 that it bought back 101,700 H-shares on the Hong Kong Stock Exchange. The transaction, executed under the company’s existing repurchase mandate, was completed at prices between HK$19.20 and HK$20.24 per share, with a volume-weighted average cost of HK$19.61 per share, bringing the total cash outlay to HK$1.99 million.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 153.49 million, down from 153.59 million prior to the transaction. Treasury shares increased to 834,900, while the company’s total issued share count, including treasury shares, remained unchanged at 154.33 million.</p>\n<p>The shares were repurchased under the authority granted by shareholders on 26 May 2026, which allows the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 834,900 shares, representing 0.54% of the issued share capital as of the mandate date.</p>\n<p>In line with Hong Kong listing rules, BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 August 2026. The board confirmed that the repurchase was duly authorised and executed in full compliance with all applicable regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B repurchases 101,700 H-shares for HK$1.99 million; treasury stock rises to 834,900 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B repurchases 101,700 H-shares for HK$1.99 million; treasury stock rises to 834,900 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-13 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B) disclosed on 13 July 2026 that it bought back 101,700 H-shares on the Hong Kong Stock Exchange. The transaction, executed under the company’s existing repurchase mandate, was completed at prices between HK$19.20 and HK$20.24 per share, with a volume-weighted average cost of HK$19.61 per share, bringing the total cash outlay to HK$1.99 million.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 153.49 million, down from 153.59 million prior to the transaction. Treasury shares increased to 834,900, while the company’s total issued share count, including treasury shares, remained unchanged at 154.33 million.</p>\n<p>The shares were repurchased under the authority granted by shareholders on 26 May 2026, which allows the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 834,900 shares, representing 0.54% of the issued share capital as of the mandate date.</p>\n<p>In line with Hong Kong listing rules, BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 August 2026. The board confirmed that the repurchase was duly authorised and executed in full compliance with all applicable regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1182059482","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182059482","pubTimestamp":1783939353,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B) disclosed on 13 July 2026 that it bought back 101,700 H-shares on the Hong Kong Stock Exchange. The transaction, executed under the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药-B以199万港元购回101,700股H股；美国库存增至 834,900 股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B) disclosed on 13 July 2026 that it bought back 101,700 H-shares on the Hong Kong Stock Exchange. The transaction, executed under the company’s existing repurchase mandate, was completed at prices between HK$19.20 and HK$20.24 per share, with a volume-weighted average cost of HK$19.61 per share, bringing the total cash outlay to HK$1.99 million.\nFollowing the repurchase, the number of issued shares (excluding treasury shares) decreased to 153.49 million, down from 153.59 million prior to the transaction. Treasury shares increased to 834,900, while the company’s total issued share count, including treasury shares, remained unchanged at 154.33 million.\nThe shares were repurchased under the authority granted by shareholders on 26 May 2026, which allows the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 834,900 shares, representing 0.54% of the issued share capital as of the mandate date.\nIn line with Hong Kong listing rules, BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 August 2026. The board confirmed that the repurchase was duly authorised and executed in full compliance with all applicable regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182059482","isCrawlerRequest":true}